Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rheumatoid arthritis: When should we use rituximab to treat RA?

× No keyword cloud information.

9 in total

1. Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes.

Authors: Allan Gibofsky; Yusuf Yazici
Journal: Ann Rheum Dis Date: 2010-06 Impact factor: 19.103

2. Treatment of rheumatoid arthritis: we are getting there.

Authors: Yusuf Yazici
Journal: Lancet Date: 2009-06-26 Impact factor: 79.321

Review 3. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations.

Authors: Y Yazici; N M Adler; H Yazici
Journal: Rheumatology (Oxford) Date: 2008-05-21 Impact factor: 7.580

4. Events per person year. Can obscure the true risk of certain adverse drug reactions.

Authors: K R Paterson
Journal: BMJ Date: 1995-06-03

5. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.

Authors: P P Tak; W F Rigby; A Rubbert-Roth; C G Peterfy; R F van Vollenhoven; W Stohl; E Hessey; A Chen; H Tyrrell; T M Shaw
Journal: Ann Rheum Dis Date: 2010-10-11 Impact factor: 19.103

6. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors: Maya H Buch; Josef S Smolen; Neil Betteridge; Ferdinand C Breedveld; Gerd Burmester; Thomas Dörner; Gianfranco Ferraccioli; Jacques-Eric Gottenberg; John Isaacs; Tore K Kvien; Xavier Mariette; Emilio Martin-Mola; Karel Pavelka; Paul P Tak; Desiree van der Heijde; Ronald F van Vollenhoven; Paul Emery
Journal: Ann Rheum Dis Date: 2011-03-06 Impact factor: 19.103

7. Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.

Authors: Y Yazici; H Yazici
Journal: Clin Exp Rheumatol Date: 2008 May-Jun Impact factor: 4.473

8. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.

Authors: S A Saunders; H A Capell; A Stirling; R Vallance; W Kincaid; A D McMahon; D R Porter
Journal: Arthritis Rheum Date: 2008-05

9. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.

Authors: Martin Soubrier; Xavier Puéchal; Jean Sibilia; Xavier Mariette; Olivier Meyer; Bernarde Combe; René Marc Flipo; Denis Mulleman; Francis Berenbaum; Charles Zarnitsky; Thierry Schaeverbeke; Patrice Fardellone; Maxime Dougados
Journal: Rheumatology (Oxford) Date: 2009-09-09 Impact factor: 7.580

9 in total

4 in total

Rheumatoid arthritis: When should we use rituximab to treat RA?

1. Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes.

2. Treatment of rheumatoid arthritis: we are getting there.

Review 3. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations.

4. Events per person year. Can obscure the true risk of certain adverse drug reactions.

5. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.

6. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

7. Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.

8. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.

9. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.

1. POLYMERIC BIOMATERIALS AND NANOMEDICINES.

2. Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines.

Review 3. Economics of non-adherence to biologic therapies in rheumatoid arthritis.

4. Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure.